-
- 1800 2010
- EN
Specialized news
Array
(
[0] => stdClass Object
(
[id] => 1259
[id_crawler] =>
[category_product] => NULL
[thumbnail] => 10.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2024-10-24
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2024-10-28 09:37:19
[updated_time] => 2025-09-08 15:21:47
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => Gentis-conquers-american-customers-at-the-asrm-2024-science-and-exhibition
[title] => GENTIS conquers American customers at the ASRM 2024 Science and Exhibition
[description] => From 21 to 23 October 2024, GENTIS was honored to be the first genetic testing unit in Vietnam having the exhibition booth at the ASRM 2024 science and exhibition held in Denver, Colorado, America. GENTIS’s booth has drawn great attention from international doctors and delegates.
[content] => GENTIS actively updates expertise in the field of assisted reproduction.
ASRM 2024 is one of the most prestigious science symposiums organized annually by the American Society for Reproductive Medicine (ASRM). Thousands of doctors, nurses, medical staff, genetic experts, embryologists, and those working in the medical sphere around the World had attended the conference. With the main theme “Equity, Access, and Innovation”, this year's event provided the latest scientific information on fertility from the world’s leading experts.
Participating at ASRM 2024 was Mr. Do Manh Ha (GENTIS CEO), Mr. Nguyen Van Huynh (GENTIS R&D center), and Mr Pham Cao Khai (GENTIS testing center). Sharing about the business trip, Mr. Do Manh Ha (GENTIS CEO) revealed “The ASRM 2024 science and exhibition draws lots of attention from doctors and embryologists. The reports’ contents at the conference are impressive and practical that are highly appreciated by the delegates. With the goal of learning and updating professional knowledge, methods and advanced genetic testing technology, the GENTIS team engaged in in-depth discussions with experts and colleagues attending the event in order to enhance testing quality and improve the success rate in in vitro fertilization (IVF) cycles.
GENTIS is always a pioneer in updating the latest knowledge and modern methods in the field of reproductive support, thereby increasing the clinical pregnancy success rate for couples trying to conceive. GENTIS has been and will be a reputable and trustworthy genetic testing unit for Vietnamese people.
GENTIS’s exhibition booth at ASRM 2024 draws widespread participation.
Held in Denver, Colorado, America, the ASRM 2024 science and exhibition symposium is one of the most renowned events in the field of reproductive support. Throughout 80 years, the symposium has become a prevalent place gathering major medical organizations around the world to seek collaborations.
Notably, GENTIS is the only genetic testing unit from Vietnam attending the conference, fortifying the company's top position in the international market when it comes to the genetic analysis field in general and assisted reproduction in particular.
With blue as the main color for brand identity, GENTIS’s booth completely stands out, drawing attention from delegates. This is a huge motivation for GENTIS to continue thriving in the journey of researching and developing genetic testing services.
At the booth , GENTIS presented high-quality genetic testing services in the field of reproductive support namely PGT-A/SR, PGT-M 100+ rare diseases, PGT-Max 1, etc. All genetic testing products of GENTIS are eligible to meet all international standards thanks to the investment in advanced technology, affirming the commitment about the great values that GENTIS can bring to both domestic and international customers.
The event not only lays a stepping stone opening great opportunities for GENTS in the journey of conquering the international market, but also puts the reproductive support field of Vietnam on the international map. In the imminent future, GENTIS will continue to grow further to become one of the world's leading units in the assisted reproduction field.
[content_more] =>
[meta_title] => GENTIS conquers American customers at the ASRM 2024 Science and Exhibition
[meta_description] => From 21 to 23 October 2024, GENTIS was honored to be the first genetic testing unit in Vietnam having the exhibition booth at the ASRM 2024 science and exhibition held in Denver, Colorado, America. GENTIS’s booth has drawn great attention from internation
[meta_keyword] => asrm,Gentis
[thumbnail_alt] =>
[post_id] => 1259
[category_id] => 15
)
[1] => stdClass Object
(
[id] => 1258
[id_crawler] =>
[category_product] => NULL
[thumbnail] => 6_-_copy.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 1
[displayed_time] => 2024-10-22
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2024-10-22 08:52:00
[updated_time] => 2025-09-08 15:21:57
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => Gentis-donates-100-free-HPV-DNA-tests-for-women-in-Phu-Ninh-District
[title] => GENTIS donates 100 free HPV - DNA tests for women in Phu Ninh District
[description] => On October 18 2024, The population Department of the Ministry of Health, in collaboration with Phu Tho Department of Health, The District Population Office, and the Phu Ninh District Health Center launched the program “For the Health of Vietnamese Women after Yagi Storm 2024”, aiming at raising awareness and providing check-ups for women affected by Yagi Storm at Phu Ninh District Health Center. GENTIS donated 100 free HPV - DNA 16 types to women in Phu Ninh District through the program. The event had the presences of Mrs. Hoang Thi Thom - Deputy Director of the Population Department, Ministry of Health; Mr. Nguyen Giang Long - Deputy Director of Phu Tho Provincial Department of Health along with representatives from GENTIS, local officials, and residents of Phu Ninh District.
[content] => GENTIS - Spreading the spirit of “Giving is Forever”
In response to the Population Department’s program and in the spirit of mutual support, as well as celebrating Vietnamese Women’s Day on October 20th, GENTIS donated 100 free HPV - DNA 16 types samples to help women in Phu Ninh District screen for and detect HPV-related health conditions in a timely manner.
The HPV - DNA test is a method using molecular biology technology to detect the presence of HPV virus (Human Papillomavirus) within the human body, especially high-risk strains that can cause cervical cancer. By undergoing the test, women will understand their health status early, enabling timely preventive measures and treatment. GENTIS is committed to provide high-quality testing services that are accurate and fast, supporting women to take care of their health effectively.
On October 18, 2024, GENTIS’s first HPV - DNA test samples were used. The examination and screening process went smoothly and received enthusiastic participation from the local community.
With the mission to bring positive value to the community, GENTIS hopes that the gift can help women in Phu Ninh District secure their health. GENTIS also looks forward to enthusiastically embracing and providing further in its humanitarian journey for the community, especially in the aftermath of Typhoon Yagi.
The program “For The Health of Vietnamese Women after Typhoon Yagi 2024” is a testament to the collective effort of the community in taking care of and protecting women’s health. With leadership from the Population Department of the Ministry of Health, along with the active participation of GENTIS and other organizations, the program has brought positive results, helping women to overcome adversities and build a better life
The 16 types HPV - DNA test at GENTIS
GENTIS is a pioneering unit in the field of genetic testing in Vietnam with over 100.000 HPV-DNA samples having been successfully conducted. GENTIS applies the advanced real-time PCR technology and DNA-DNA hybridization on Nitrocellulose membranes for HPV-DNA testing, enabling accurate screening of risks related to cervical cancer.
Additionally, the DNA - HPV test at GENTIS has fast result turnover and competitive price for those having demands. Let us work together towards a healthy, hopeful Vietnam, where every woman is loved, cared for, and has the opportunity to develop fully.
[content_more] =>
[meta_title] => GENTIS donates 100 free HPV - DNA tests for women in Phu Ninh District
[meta_description] => On October 18 2024, The population Department of the Ministry of Health, in collaboration with Phu Tho Department of Health, The District Population Office, and the Phu Ninh District Health Center launched the program “For the Health of Vietnamese Women a
[meta_keyword] =>
[thumbnail_alt] =>
[post_id] => 1258
[category_id] => 15
)
[2] => stdClass Object
(
[id] => 1257
[id_crawler] =>
[category_product] => NULL
[thumbnail] => dsc08351.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2024-10-17
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2024-10-17 09:23:09
[updated_time] => 2025-09-08 15:22:19
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => Gentis-sparks-a-strong-impression-at-the-vietnam-france-obstetrics-and-gynecology-conference-2024
[title] => GENTIS sparks a Strong Impression at the Vietnam-France Obstetrics and Gynecology Conference 2024
[description] => With the most advanced genetic testing products and services in the field of obstetrics and gynecology, GENTIS's booth attracted a large number of doctors and specialists visiting to learn more at the Vietnam-France Obstetrics and Gynecology Conference 2024
[content] => The conference officially opened on October 14 at the JW Marriott Hotel, No. 8 Do Duc Duc, Hanoi. This important event marks the professional cooperation in healthcare between the governments of Vietnam and France, attracting thousands of professors, doctors, and specialists from both domestic and international backgrounds.
Organized by the Central Obstetrics and Gynecology Hospital in collaboration with the French Obstetrics and Gynecology Association (CNGOF), the conference featured over 70 high-quality scientific presentations alongside lively discussions on the most pressing topics in obstetrics, gynecology, and reproductive support.
The presentations were divided into various sessions with diverse themes, catering to the interests of attendees. This facilitated the identification of issues and solutions, enabling doctors and specialists to find the best treatment directions in healthcare, particularly in reproductive health.
Attendees not only accessed the latest knowledge in obstetrics, gynecology, and reproductive support but also had the opportunity to meet leading experts and network with colleagues both domestically and internationally to share and update professional knowledge.
At this Vietnam-France Obstetrics and Gynecology Conference, GENTIS was honored to be the main sponsor. At the exhibition area, GENTIS's booth garnered significant interest from attending doctors and specialists in obstetrics, gynecology, and reproductive support. GENTIS introduced its most advanced genetic testing products and services, prominently featuring the GenEva 92 (NIPT IVD) test. This non-invasive prenatal screening test helps screen for syndromes related to genetic abnormalities in the fetus by analyzing cfDNA from the mother's blood starting from the 10th week of pregnancy, ensuring safety and an accuracy rate exceeding 99%.
GenEva 92: An Essential Tool in Modern Prenatal Care
GenEva 92 is recognized as a crucial instrument in modern prenatal care due to its outstanding advantages:
The process is fully automated, from sample extraction to result analysis, minimizing direct handling by technicians. This significantly reduces human error, leading to more accurate and stable results, with sensitivity and specificity proven to exceed 99%.
The GenEva 92 test employs IVD-certified reagents, from cfDNA extraction chemicals to next-generation sequencing reagents.
Its proprietary result analysis software, certified CE-IVD, ensures high accuracy. This is a significant advantage that other NIPT test packages on the market do not currently offer.
GenEva 92 provides an expanded testing solution, identifying the following abnormalities:
- Three common aneuploidy syndromes in fetuses: Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
- Four additional syndromes: XO (Turner syndrome), XXX (Triple X syndrome), XXY (Klinefelter syndrome), and XYY (Jacobs syndrome).
- Aneuploidy across all remaining chromosomes.
- 92 microdeletion/duplication abnormalities related to common genetic syndromes, including Prader-Willi/Angelman (15q11.2), DiGeorge (22q11.2), and Cri du Chat.
Moreover, GENTIS has assembled a team of highly skilled and experienced genetic doctors and specialists, ensuring thorough consultation for expectant mothers before and after testing, along with comprehensive support policies. This demonstrates GENTIS's commitment to accompanying Vietnamese mothers on their journey to care for the health of future generations.
Through the Vietnam-France Obstetrics and Gynecology Conference, GENTIS has brought the GenEva 92 testing service closer to specialists and doctors in the obstetrics and gynecology field across the country. On October 14 and 15, 2024, GENTIS's booth welcomed hundreds of attendees interested in its products and services. Engaging games with guaranteed prizes, including the exclusive translation of "Male Infertility Through a Genetic Lens" and "Genetic Abnormalities in Male Infertility" by Dr. Trinh The Son, as well as vouchers for PRP kits and water bottles, were distributed to attendees.
The GENTIS product display received significant interest from numerous delegates and guests. Here, the questions and concerns of doctors regarding GENTIS’s genetic testing services were addressed in detail. Notably, physicians and specialists highly valued GENTIS's genetic tests in obstetrics and reproductive support.
Through its service introduction at the conference, GENTIS hopes to continue collaborating with doctors, specialists, hospitals, and clinics in delivering accurate and timely genetic testing to the Vietnamese population. With the mission to enhance the physical and intellectual well-being of Vietnamese people, GENTIS is committed to continually updating, researching, and developing genetic testing services to improve screening quality and healthcare for the community.
[content_more] => [meta_title] => GENTIS sparks a Strong Impression at the Vietnam-France Obstetrics and Gynecology Conference 2024 [meta_description] => With the most advanced genetic testing products and services in the field of obstetrics and gynecology, GENTIS's booth attracted a large number of doctors and specialists visiting to learn more at the Vietnam-France Obstetrics and Gynecology Conference 20 [meta_keyword] => GENTIS,obstetrics and gynecology [thumbnail_alt] => [post_id] => 1257 [category_id] => 15 ) [3] => stdClass Object ( [id] => 1255 [id_crawler] => [category_product] => NULL [thumbnail] => web.png [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-10-11 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-10-14 09:40:42 [updated_time] => 2025-09-08 15:22:31 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Gentis-accompanies-the-Vietnam-France-obstetrics-and-gynecology-conference-2024 [title] => GENTIS accompanies the Vietnam-France Obstetrics and Gynecology Conference 2024. [description] => The Vietnam-France Obstetrics and Gynecology Conference 2024 is an important event that marks the professional collaboration in the medical field between Vietnam and France governments. The conference is organized by the Central Obstetrics and Gynecology Hospital and Tu Du Hospital in collaboration with the French National College of Obstetrics and Gynecology (CNGOF). [content] =>This year, the Vietnam-France Obstetrics and Gynecology Conference has been expanded. Besides France experts, the organizer also invites numerous obstetrics and gynecology specialists coming from various countries, facilitated by existing diplomatic relations. This marks the event as a highly anticipated scientific forum for the global obstetrics and gynecology community. The Vietnam-France Obstetrics and Gynecology Conference 2024 will be held two days, October 14-15 at the JW Marriott Hotel, No. 8 Do Duc Duc, Ha Noi and will be broadcasted live on Zoom platform.
At the conference, the delegates will have a chance to update the latest information about clinical practice guidelines, controversial issues and advancements in the fields such as obstetrics, gynecology, oncology, reproductive assistance, prenatal diagnosis, pelvic medicine, and neonatology.
Continuing its support for the Vietnam-France Obstetrics and Gynecology conference 2024 as a sponsor, GENTIS will bring an impressive booth with an engaging design, featuring modern genetic testing services in the obstetrics and gynecology sector such as GenEva, Thalassemia, etc. Additionally, the attendees will have an opportunity to take part in exciting mini-games, lucky draws, with practical and meaningful gifts to be won.
We look forward to welcoming all doctors and experts at the GENTIS booth during the Vietnam-France Obstetrics and Gynecology Conference 2024!
[content_more] => [meta_title] => GENTIS accompanies the Vietnam-France Obstetrics and Gynecology Conference 2024. [meta_description] => The Vietnam-France Obstetrics and Gynecology Conference 2024 is an important event that marks the professional collaboration in the medical field between Vietnam and France governments [meta_keyword] => Gentis,Obstrettrics and Gynecology [thumbnail_alt] => [post_id] => 1255 [category_id] => 15 ) [4] => stdClass Object ( [id] => 1254 [id_crawler] => [category_product] => NULL [thumbnail] => Ảnh_trao_hb_ct_gentis_1.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-10-11 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-10-11 15:57:47 [updated_time] => 2025-09-08 15:22:36 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Gentis-awards-scholarships-to-2-resident-doctors- in-genetic-biomedical-science-at-hanoi-university-of-medicine [title] => GENTIS awards scholarships to 2 resident doctors in Genetic Biomedical Science at Hanoi University of Medicine [description] => With the wish to spread the love and positive values, on october 11, 2024, at the main hall of Hanoi University of Medicine, GENTIS, in collaboration with Hanoi University of Medicine organized scholarship award ceremony worth 60,000,000 VND for 02 resident doctors in Genetic Biomedical Science (30,000,000 VND per scholarship). [content] =>The ceremony is a meaningful event, greatly helping the students to relieve the financial burden as well as create positive motivations for them to continue striving in their studies and life. Representing the university were Assoc. Prof. Nguyen Manh Ha, Dr. Nguyen Hoang Thanh accompanied numerous teachers and resident students.
On behalf of GENTIS, Mr. Do Manh HA (CEO) and Mr. Pham Dinh Minh (Director of R&D department) attended the event. At the ceremony, Mr. Do Manh Ha personally awarded the two scholarships to resident doctor Phan Hoang Cuc - Class 46, specializing in Genetic Biomedical Science, and resident doctor Dao Thi Huyen Trang - Class 46, specializing in Genetic Biomedical Science.
GENTIS would like to express our congratulations towards the awarded resident students with the hope that they will continue to strive academically to become great doctors who meaningfully contribute to society. The Board of Directors of Hanoi University of Medicine has expressed their sincere gratitude to GENTIS for their special attention to students facing difficult circumstances, encouraging them to overcome challenges and achieve outstanding academic results.
The GENTIS scholarship is a meaningful reward, providing the resident doctors in Genetic Biomedical Science with additional confidence and support in their studies and training, motivating them to become exemplary doctors in society. As a private organization with 14 years of development, GENTIS has established a strong brand in the field of genetic analysis.
In addition to its continuous efforts to develop its expertise and enhance the quality of genetic testing, GENTIS places great importance on participating in community-oriented charitable activities. GENTIS hopes to contribute even more to its mission of kindness, spreading the message that “giving is everlasting,” and working together to build a sustainable and thriving society.
[content_more] => [meta_title] => GENTIS awards scholarships to 2 resident doctors in Genetic Biomedical Science at Hanoi University [meta_description] => GENTIS, in collaboration with Hanoi University of Medicine organized scholarship award ceremony worth 60,000,000 VND for 02 resident doctors in Genetic Biomedical Science (30,000,000 VND per scholarship). [meta_keyword] => Gentis,Scholarship,Charity [thumbnail_alt] => [post_id] => 1254 [category_id] => 15 ) [5] => stdClass Object ( [id] => 1112 [id_crawler] => [category_product] => NULL [thumbnail] => thiết_kế_chưa_co_ten_(5).jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2023-07-20 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2023-07-20 15:20:07 [updated_time] => 2023-08-22 14:12:50 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => y-nghia-cua-xet-nghiem-da-hinh-gen-thu-the-fsh-trong-ho-tro-sinh-san [title] => Significance of FSH receptor gene polymorphism test in assisted reproduction [description] => FSH is a hormone released from the anterior pituitary gland in the brain. FSH stimulates the development of immature oocytes. FSH receptor gene polymorphism testing allows the identification of genetic variants associated with the response to ovarian stimulation. [content] =>1. What is FSH hormone?
.jpg)
FSH (Folicle Stimulating Hormone) is a hormone released from the anterior pituitary gland in the brain. FSH stimulates the development of immature oocytes.
At the beginning of development, the oocyte releases estradiol, which in turn acts on the hypothalamus and pituitary gland to increase the release of GnRH and LH, promoting ovulation. Before ovulation, FSH levels peak, stimulating the ovaries and causing ovulation. Once ovulation has occurred, FSH levels return to baseline or drop slightly below normal.
2. Significance of FSH receptor gene polymorphism test in assisted reproduction
The FSH receptor gene polymorphism test is a test that allows the identification of genetic variants associated with the response to ovarian stimulation. The aim is to produce good quality embryos and increase pregnancy rates in IVF.
.jpg)
When ovarian stimulation is performed, depending on the response of the ovaries, the results can be classified into 4 main groups:
• Poor responder according to Bologna criteria: 3 oocytes obtained
• Sub-optimal responder: 4 to 9 oocytes obtained
• Normal responder: 10 to 15 oocytes are obtained
• Hyper-responder: ≥ 15 oocytes obtained
Therefore, the identification and classification of patients is the key to choosing the correct treatment strategy. Currently, poor response to ovarian stimulation is a matter of great concern because this is a very difficult patient group to treat in IVF.
In addition to the problems of ovarian reserve factors such as AFC secondary follicles, AMH hormones, body mass index (BMI), age of the patient, etc., many studies show that FSH receptor gene polymorphisms associated with poor ovarian response.
In Vietnam, FSH receptor gene polymorphism testing is still relatively new. However, in the world, there have been many studies showing that some FSH receptor gene polymorphisms make the amount of drugs that patients need to take more. The four SNPs that have been shown to be associated with poor ovarian response are rs6165, rs6166, rs1394205, rs10835638.
FSH receptor gene polymorphism testing will be a promising and necessary option for individualizing ovarian stimulation and obtaining optimal egg numbers for treatments.
.jpg)
If the patient is a carrier of the FSH receptor gene polymorphism associated with poor ovarian response, the dose of the drug will need to be increased in order to obtain the optimal number of eggs. Like this, the patient will have to stimulate more times, which means an increase in treatment costs. Therefore, we should screen at the beginning to classify the patient into which group.
The FSH receptor gene polymorphism test has been studied and proven to be associated with poor ovarian response, and supports physicians in individualizing and optimizing ovarian stimulation regimens. By performing the FSH receptor gene polymorphism test, the doctor will provide an optimal and personalized ovarian stimulation regimen for each patient, as well as assist in determining the cause of the poor ovarian response. (POR).
It can be seen that performing FSH receptor polymorphism testing is extremely important for women who are about to undergo ovarian stimulation. By performing this test, the doctor will come up with an effective treatment plan, helping infertility cases save time and costs as well as soon "harvest the sweet fruit".
1. What is the PGT-M test?
PGT-M is a pre-embryo transfer genetic test for monogenic inherited diseases. With this test, we can test the embryo's genome very early, helping to detect abnormal passages on a particular gene inherited from parents.
From there, the embryos that are homozygous for the disease gene will be removed before being transferred to the mother's uterus. The effectiveness of the PGT-M test has been shown to limit the number of babies born with thalassemia and the need to terminate the pregnancy mid-term when the fetus has severe anemia abnormalities.
Not only effective in diagnosing thalassemia, the PGT-M test also helps diagnose many other single-gene diseases in embryos such as X-linked genetic diseases, dystrophy Duchenne muscle, Hemophilia,... Moreover, in the future, this test is also aimed at treating siblings of children who have been born but have the disease.
In addition, the PGT-M test can diagnose the human leukocyte antigen (HLA) match of the embryo with the affected sibling. Stem cells from the cord blood of children born from embryos selected through PGT-M will help treat siblings with the disease.
2. Who should perform the PGT-M test?
The PGT-M test is ordered by the doctor in cases where there is a history of a husband or wife carrying the disease gene, or in the family there is an inherited disease caused by a gene mutation such as monodominant inherited diseases (eg. Huntington's disease), monogenic recessive diseases (eg, cystic fibrosis), chromosomal disorders (eg, numerical or structural abnormalities), sex-linked disorders (eg, Duchenne muscular dystrophy), predictors of cancer (cervical cancer, breast cancer, etc.) or determine HLA compatibility (to select embryos compatible with HLA antigens with siblings). have a disease that requires blood transfusion, marrow transplant. This child can later cure the disease, donate marrow for brother/sister).
For patients at risk of passing a genetic disease on to their children, PGT-M reduces the risk and increases the likelihood of having a healthy baby. Also avoid emotionally and ethically challenging decisions when deciding whether to terminate a pregnancy if the fetus has a genetic abnormality.
In clinical practice, PGT-M is often combined with the PGT-A/SR test to comprehensively assess embryo quality and improve the success rate of assisted reproduction methods. Patients with single-gene disorders are mostly young and have a good prognosis, but their risk of spontaneous abortion is still quite high. In recent years, many studies have reported that when embryos are combined with PGT-M and PGT-A screening, the pregnancy rate can increase from 45 to 68% and the rate of spontaneous abortion decreases from 15% to 15%. 5%.
In addition, the combination of PGT-A screening is appropriate for the majority of women undergoing IVF. All women are at risk of producing embryos with chromosomal abnormalities (trisomy 13, 18, 21), and as maternal age increases, the likelihood of embryos with chromosomal abnormalities increases. However, the PGT-A test can help women of all ages increase their chances of successful fertilization and embryo transfer.
3. How is the PGT-M test done?
Basically, to perform the PGT-M test, couples need to be assisted with IVF. The generated embryos will be raised to day 5.
With the eligible embryos on day 5 (blastocysts) will be biopsied (removing 3 - 5 embryonic cells from the cell area that will develop into the placenta later). Cell samples after biopsy will be applied special testing methods to detect disease-carrying genes.
With modern medicine, today, we can also perform the ASEM test on the embryo culture medium sample without the need for an embryo biopsy. With this technique, we do not need to worry about possible effects on the embryo during the biopsy.
4. The purpose of PGT-M for families with inherited diseases to have healthy children
According to research, the current infertility rate in Vietnam accounts for 7.7%, of which the causes are equal to men and women, accounting for 40% of each gender and 20% of unknown causes. The development and rapid progress of genetic engineering and technologies have greatly benefited the field of assisted reproduction right from the pre-implantation embryo stage.
The PGT method (pre-implantation embryo screening) has greatly contributed to the selection of the healthiest embryos before implantation in the uterus, increasing the chances of pregnancy, reducing the number of cycles of in vitro fertilization and the cost of pay. In addition, PGT-M is a test to identify abnormalities, single gene mutations associated with some genetic disease syndromes such as Thalassemia, Hemophilia, muscular atrophy, polycystic kidney, RETT syndrome,... PGT -M is indicated for couples who carry a disease-causing mutation and are at high risk of having a child with a monogenic disease.
The effectiveness of the PGT-M test has been clearly demonstrated to help limit the situation of babies being born with the disease, limiting the need to terminate the pregnancy midway when the fetus has an abnormal diagnosis. With dangerous genetic diseases, the implementation of prenatal genetic screening and diagnosis is no longer an individual affair of a family, but a long-term step with the contribution of society in general and the medical profession. economy in particular.
For the purpose of improving, improving the quality of the race, and the prosperity of society, PGT-M will improve the status of children born with birth defects, serious genetic diseases and non-reproductive abnormalities. desired in couples.
5. GENTIS - Comprehensive gene ecosystem for Vietnamese people
With the desire to bring the best fertility support methods to doctors and patients in Vietnam, GENTIS has constantly researched, developed, and applied the PGT-M test in preimplantation embryo screening with rare diseases. Not only effective in diagnosing Thalassemia, PGT-M technique also helps diagnose many other rare genetic diseases of embryos such as myelodysplasia, Duchenne muscular dystrophy, hemophilia, osteochondrotic dysplasia. , congenital adrenal hyperplasia, hemophagocytic syndrome, marfan syndrome, autosomal dominant polycystic kidney, iris defect, congenital hearing loss, RETT syndrome,...
At GENTIS, along with the application of new technical technologies, using modern machinery systems (new generation DNA sequencing system NGS Illumina - USA, Veriseq PGS technology) and specialized analysis software Using (STR, SNP analytical methods), the PGT-M test was developed and performed rigorously to provide the most reliable results.
Combining PGT-M screening for single-gene genetic disease with PGT-A screening for aneuploidy embryos will help couples select embryos that do not carry genetic abnormalities to be screened for embryo transfer. With modern technology increasingly developed, GENTIS hopes to deploy, research, and successfully test many other rare genetic diseases, contributing to the successful preimplantation screening process and healthy babies for every family.
With a system of 2 laboratories meeting ISO 9001:2015, ISO 15189:2012 and the ability to perform tens of thousands of tests per year, GENTIS always aims to develop gene technology suitable for Vietnamese people, bringing has great value in the diagnosis, treatment of diseases and assisted reproduction. In particular, GENTIS is increasingly asserting its outstanding position in the field of genetic analysis, maintaining full trust for customers and partners.
GENTIS conquers American customers at the ASRM 2024 Science and Exhibition
GENTIS donates 100 free HPV - DNA tests for women in Phu Ninh District
GENTIS sparks a Strong Impression at the Vietnam-France Obstetrics and Gynecology Conference 2024
GENTIS accompanies the Vietnam-France Obstetrics and Gynecology Conference 2024.
GENTIS awards scholarships to 2 resident doctors in Genetic Biomedical Science at Hanoi University of Medicine
-360x194.jpg)
Significance of FSH receptor gene polymorphism test in assisted reproduction
Significance and importance of PGT-M for families with genetic diseases to have healthy children
GENTIS ghi dấu ấn tại Hội nghị Sản Phụ khoa Việt - Pháp - Châu Á - Thái Bình Dương
Please fill in the information below to receive our supports and consultations!
Please fill in the information below to receive our supports and consultations!
